Interaction reference

GLP-1 receptor agonists with SSRIs

No documented pharmacokinetic interaction. Anecdotally, GLP-1 users on SSRIs sometimes report a clearer "food noise" reduction effect.

Continue your SSRI. No dose change needed.

Also known as: sertraline, escitalopram, fluoxetine, Zoloft, Lexapro, Prozac

Per-GLP-1 breakdown

Wegovysemaglutide 2.4 mg
No documented interaction
Mechanism: Different metabolic pathways. SSRIs metabolized via CYP2D6/3A4; GLP-1s are peptide drugs (semaglutide, tirzepatide) cleared without significant CYP involvement, or orally absorbed small molecule (orforglipron) with minimal CYP impact.
What to do: Continue current SSRI. Monitor for emerging GI side effects in the first 2 weeks, as both can affect appetite/nausea.
Zepboundtirzepatide
No documented interaction
Mechanism: Different metabolic pathways. SSRIs metabolized via CYP2D6/3A4; GLP-1s are peptide drugs (semaglutide, tirzepatide) cleared without significant CYP involvement, or orally absorbed small molecule (orforglipron) with minimal CYP impact.
What to do: Continue current SSRI. Monitor for emerging GI side effects in the first 2 weeks, as both can affect appetite/nausea.
Ozempicsemaglutide
No documented interaction
Mechanism: Different metabolic pathways. SSRIs metabolized via CYP2D6/3A4; GLP-1s are peptide drugs (semaglutide, tirzepatide) cleared without significant CYP involvement, or orally absorbed small molecule (orforglipron) with minimal CYP impact.
What to do: Continue current SSRI. Monitor for emerging GI side effects in the first 2 weeks, as both can affect appetite/nausea.
Mounjarotirzepatide
No documented interaction
Mechanism: Different metabolic pathways. SSRIs metabolized via CYP2D6/3A4; GLP-1s are peptide drugs (semaglutide, tirzepatide) cleared without significant CYP involvement, or orally absorbed small molecule (orforglipron) with minimal CYP impact.
What to do: Continue current SSRI. Monitor for emerging GI side effects in the first 2 weeks, as both can affect appetite/nausea.
Foundayoorforglipron
No documented interaction
Mechanism: Different metabolic pathways. SSRIs metabolized via CYP2D6/3A4; GLP-1s are peptide drugs (semaglutide, tirzepatide) cleared without significant CYP involvement, or orally absorbed small molecule (orforglipron) with minimal CYP impact.
What to do: Continue current SSRI. Monitor for emerging GI side effects in the first 2 weeks, as both can affect appetite/nausea.

Sources

SSRI coadministration with GLP-1 receptor agonists (opens in a new tab) — Lexicomp drug interaction database

See other interactions

Full interaction index